Structural formula: Vismodegib

ERIVEDGE 150 mg, hard capsule 28 capsules

Telegram WhatsApp

Link to share

Active ingredients: Vismodegib

Commercialized according to BDPMDispensing in France: Prescription only

Hard capsule28 capsulesorale

No current ANSM shortage notice is included

Package details

Original BDPM fields are shown in French.

Official name: ERIVEDGE 150 mg, gélule
Pharmaceutical form: gélule
Route of administration: orale
Presentation description: 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 28 gélule(s)
Marketing authorisation holder: ROCHE REGISTRATION (ALLEMAGNE)
Reimbursement according to BDPM: 100%
Approval for use in healthcare institutions: oui
Commercialization declaration date: 11 Oct 2013
Prescription and dispensing conditions: Prescription only
List I: prescription-only medicine
Requires special monitoring during treatment
Prescribed by a hospital doctor
Prescribed by specialists only
Original BDPM wording: liste I · médicament nécessitant une surveillance particulière pendant le traitement · pour les femmes susceptibles de procréer : surveillance particulière pendant le traitement · prescription hospitalière · prescription nécessitant préalablement le recueil de l’accord de soins du patient · prescription réservée aux médecins compétents en CANCEROLOGIE · prescription réservée aux spécialistes et services ONCOLOGIE MEDICALE
Enhanced ANSM monitoring: No

BDPM identifiers

CIS67507605CIP72747677CIP133400927476778

Composition in BDPM

Composition in BDPM
Component	Amount per unit	Source type
VISMODÉGIBgélule	150 mg · une gélule	SA

Information is based on BDPM data and is for reference only. Consult a doctor before use.

Similar medicines

Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.

The current BDPM data does not list similar medicines for this product.